Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations

Detalhes bibliográficos
Autor(a) principal: Carda, José Pedro
Data de Publicação: 2021
Outros Autores: Santos, Lurdes, Mariz, José Mário, Monteiro, Pedro, Gonçalves, Humberto Miguel, Raposo, João, Silva, Maria Gomes da
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/101177
https://doi.org/10.1080/16078454.2021.1980690
Resumo: Ibrutinib, a potent inhibitor of the Bruton tyrosine kinase, has revolutionized the treatment of many B-cell malignancies. Ibrutinib has an established favorable toxicity profile with up to 8 years of experience in clinical trials; however, despite ibrutinib's favorable toxicity profile, dose reductions and treatment discontinuations are becoming more evident in clinical practice, particularly in the setting of specific clinical contexts and patient characteristics. This manuscript is set to provide practical recommendations on the management of patients treated with this agent in daily practice.
id RCAP_30fa8a28737ba68496c0337aec99a8e0
oai_identifier_str oai:estudogeral.uc.pt:10316/101177
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendationsB-cell malignanciesBruton tyrosine kinase inhibitoribrutinibrecommendationsIbrutinib, a potent inhibitor of the Bruton tyrosine kinase, has revolutionized the treatment of many B-cell malignancies. Ibrutinib has an established favorable toxicity profile with up to 8 years of experience in clinical trials; however, despite ibrutinib's favorable toxicity profile, dose reductions and treatment discontinuations are becoming more evident in clinical practice, particularly in the setting of specific clinical contexts and patient characteristics. This manuscript is set to provide practical recommendations on the management of patients treated with this agent in daily practice.2021-12info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/101177http://hdl.handle.net/10316/101177https://doi.org/10.1080/16078454.2021.1980690eng1607-84541607-845434605364346053641607-8454346053641607-8454Carda, José PedroSantos, LurdesMariz, José MárioMonteiro, PedroGonçalves, Humberto MiguelRaposo, JoãoSilva, Maria Gomes dainfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-08-16T20:49:38Zoai:estudogeral.uc.pt:10316/101177Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:18:25.668694Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations
title Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations
spellingShingle Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations
Carda, José Pedro
B-cell malignancies
Bruton tyrosine kinase inhibitor
ibrutinib
recommendations
title_short Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations
title_full Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations
title_fullStr Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations
title_full_unstemmed Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations
title_sort Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations
author Carda, José Pedro
author_facet Carda, José Pedro
Santos, Lurdes
Mariz, José Mário
Monteiro, Pedro
Gonçalves, Humberto Miguel
Raposo, João
Silva, Maria Gomes da
author_role author
author2 Santos, Lurdes
Mariz, José Mário
Monteiro, Pedro
Gonçalves, Humberto Miguel
Raposo, João
Silva, Maria Gomes da
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Carda, José Pedro
Santos, Lurdes
Mariz, José Mário
Monteiro, Pedro
Gonçalves, Humberto Miguel
Raposo, João
Silva, Maria Gomes da
dc.subject.por.fl_str_mv B-cell malignancies
Bruton tyrosine kinase inhibitor
ibrutinib
recommendations
topic B-cell malignancies
Bruton tyrosine kinase inhibitor
ibrutinib
recommendations
description Ibrutinib, a potent inhibitor of the Bruton tyrosine kinase, has revolutionized the treatment of many B-cell malignancies. Ibrutinib has an established favorable toxicity profile with up to 8 years of experience in clinical trials; however, despite ibrutinib's favorable toxicity profile, dose reductions and treatment discontinuations are becoming more evident in clinical practice, particularly in the setting of specific clinical contexts and patient characteristics. This manuscript is set to provide practical recommendations on the management of patients treated with this agent in daily practice.
publishDate 2021
dc.date.none.fl_str_mv 2021-12
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/101177
http://hdl.handle.net/10316/101177
https://doi.org/10.1080/16078454.2021.1980690
url http://hdl.handle.net/10316/101177
https://doi.org/10.1080/16078454.2021.1980690
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1607-8454
1607-8454
34605364
34605364
1607-8454
34605364
1607-8454
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1817549948384706560

Registros relacionados